We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
- Authors
van der Lely, A J; Hutson, R K; Trainer, P J; Besser, G M; Barkan, A L; Katznelson, L; Klibanski, A; Herman-Bonert, V; Melmed, S; Vance, M L; Freda, P U; Stewart, P M; Friend, K E; Clemmons, D R; Johannsson, G; Stavrou, S; Cook, D M; Phillips, L S; Strasburger, C J; Hackett, S; Zib, K A; Davis, R J; Scarlett, J A; Thorner, M O
- Abstract
Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days.
- Publication
Lancet (London, England), 2001, Vol 358, Issue 9295, p1754
- ISSN
0140-6736
- Publication type
Journal Article
- DOI
10.1016/s0140-6736(01)06844-1